Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: Subgroup analysis of a randomized phase 3 trial

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Zinzani, Pier Luigi ^a   Khuageva, Nuriet K ^b   Wang, Huaqing ^c   Garicochea, Bernardo ^d   Walewski, Jan ^e   Van Hoof, Achiel ^f   Soubeyran, Pierre ^g   Caballero, Dolores ^h   Buckstein, Rena ⁱ   Esseltine, Dixie Lee ^j   Theocharous, Panteli ^k   Enny, Christopher ^l   Zhu, Eugene ^l   Elsayed, Yusri A ^l   Coiffier, Bertrand ^m  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SP Botkin Moscow City Clinical Hospital   (Russian Federation)

^c KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^d Hospital São Lucas   (Brazil)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f General Hospital St Jan   (Belgium)

^g INSTITUT BERGONIÉ   (France)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^j MILLENNIUM PHARMACEUTICALS INC   (United States)

^k Oncology R and D   (United Kingdom)

^l Oncology R and D   (United States)

^m HOSPICES CIVILS DE LYON   (France)

more..

Author keywords

Bortezomib; Follicular; High risk; Lymphoma; Rituximab

Indexed keywords

BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SENSORY NEUROPATHY; SEPTIC SHOCK; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PYRAZINES;

EID: 84867641179     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-67     Document Type: Article

References (38)

1. Treatment of follicular non-Hodgkin's lymphoma: the old and the new. Friedberg JW, Semin Hematol 2008 45 2 S6 18760706
2. Follicular lymphoma: emerging therapeutic strategies. Kenkre VP, Kahl BS, Expert Rev Hematol 2010 3 485 495 10.1586/ehm.10.45 21083037
3. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, et al. Lancet 2011 377 42 51 10.1016/S0140-6736(10)62175-7 21176949
4. Follicular lymphoma. Ghielmini M, Ann Oncol 2010 21 &22ii151 vii153 10.1093/annonc/mdq287 20943608
5. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, et al. J Clin Oncol 2006 24 1582 1589 10.1200/JCO.2005.03.3696 16575009
6. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, et al. J Clin Oncol 2009 27 4555 4562 10.1200/JCO.2008.21.3991 19652063
7. Follicular lymphoma international prognostic index. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Rranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, et al. Blood 2004 104 1258 1265 10.1182/blood-2003-12-4434 15126323
8. Prognostic tools in follicular lymphomas. Luminari S, Cox MC, Montanini A, Federico M, Expert Rev Hematol 2009 2 549 562 10.1586/ehm.09.34 21083020
9. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Solal-Celigny P, Cahu X, Cartron G, Int J Hematol 2010 92 246 254 10.1007/s12185-010-0674-x 20803352
10. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Montoto S, Lopez-Guillermo A, Altes A, Perea G, Ferrer A, Camos M, Villela L, Bosch F, Esteve J, Cervantes F, et al. Ann Oncol 2004 15 1484 1489 10.1093/annonc/mdh406 15367408
11. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients. Formica V, Norman AR, Cunningham D, Wotherspoon A, Oates J, Chong G, Acta Haematol 2009 122 193 199 10.1159/000253026 19887775
12. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires, Groupe d'Etude des Lymphomes de l'Adulte. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Celigny P, J Clin Oncol 1997 15 1110 1117 9060552
13. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucemies et Autres Maladies du Sang (GOELAMS). Morschhauser F, Mounier N, Sebban C, Brice P, Solal-Celigny P, Tilly H, Feugier P, Ferme C, Copin MC, Lamy T, Cancer 2010 116 4299 4308 10.1002/cncr.25280 20549824
14. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases Intergruppo Italiano Linfomi. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P, et al. Blood 2000 95 783 789 10648386
15. Prognostic factors in follicular lymphoma. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD, J Clin Oncol 2010 28 2902 2913 10.1200/JCO.2009.26.1693 20385990
16. Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice. Rummel M, J Natl Compr Canc Netw 2010 8 1 S14 20947719
17. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, et al. J Clin Oncol 2008 26 4579 4586 10.1200/JCO.2007.13.5376 18662969
18. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, et al. Blood 2004 104 3064 3071 10.1182/blood-2004-04-1323 15284112
19. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, et al. Ann Oncol 2008 19 553 559 18083690
20. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, Veer M, Vranovsky A, Holte H, et al. J Clin Oncol 2010 28 2853 2858 10.1200/JCO.2009.26.5827 20439641
21. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D, Cochran EW Jr, Dien PY, Lyons R, Schlegel PJ, et al. Blood 2010 115 475 480 10.1182/blood-2009-08-233155 19965689
22. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, Gonen M, Dumitrescu O, Sarasohn D, Butos J, et al. Clin Cancer Res 2010 16 719 726 10.1158/1078-0432.CCR-08-2647 20068103
23. Final results of a randomized phase 2 multicenter study of two bortezomib schedules in patients with recurrent or refractory follicular lymphoma. Groupe d'Etude Des Lymphomes De l'Adulte (GELA) study FL-05 [abstract]. Ribrag V, Tilly H, Casasnovas O, Bosly A, Bouabdullah R, Delarue R, Boue F, Bron D, Feugier P, Haioun C, et al. Blood 2010 116 338a
24. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Agathocleous A, Rohatiner A, Rule S, Hunter H, Kerr JP, Neeson SM, Matthews J, Strauss S, Montoto S, Johnson P, et al. Br J Haematol 2010 151 346 353 10.1111/j.1365-2141.2010.08340.x 20880120
25. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, et al. J Clin Oncol 2009 27 5023 5030 10.1200/JCO.2008.17.7980 19770386
26. Weekly infusion of bortezomib in combination with rituximab in relapsed/refractory indolent non-follicular and mantle cell lymphoma is safe and effective: two-years analysis of phase II trial BRIL06 of Intergruppo Italiano Linfomi (IIL) [abstract]. Chiappella A, Pregno P, Zinzani PL, Evangelista A, Fabbri A, Facchetti F, Ferreri AJM, Franceschetti S, Freilone R, Gargantini L, et al. Blood 2010 116 1617a
27. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA, Cancer 2011 117 2442 2451 10.1002/cncr.25792
28. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, De VS, et al. Lancet Oncol 2011 12 773 784 10.1016/S1470-2045(11)70150-4 21724462
29. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival-a study from the Groupe d'Etude des Lymphomes de l'Adulte. Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le GS, Delmer A, Bordessoule D, Tilly H, Corront B, et al. J Clin Oncol 2010 28 822 829 10.1200/JCO.2009.22.7819 20026809
30. Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. van de Schans SA, Steyerberg EW, Nijziel MR, Creemers GJ, Janssen-Heijnen ML, van Spronsen DJ, Ann Oncol 2009 20 1697 1702 10.1093/annonc/mdp053 19549712
31. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, Weisenburger DD, Armitage JO, Biol Blood Marrow Transplant 2008 14 36 42 18158959
32. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Ann Oncol 2011 22 Suppl 6 &22i59 vi63 21908506
33. Non-Hodgkin's lymphomas. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, et al. J Natl Compr Canc Netw 2011 9 484 560 21550968
34. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ, Clin Cancer Res 2008 14 1561 1570 10.1158/1078-0432.CCR-07-1254 18316581
35. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Jazirehi AR, Vega MI, Bonavida B, Cancer Res 2007 67 1270 1281 10.1158/0008-5472.CAN-06-2184 17283164
36. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Vega MI, Martinez-Paniagua M, Jazirehi AR, Huerta-Yepez S, Umezawa K, Martinez-Maza O, Bonavida B, Leuk Lymphoma 2008 49 1982 1994 10.1080/10428190802357071 18949621
37. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD, J Clin Oncol 1999 17 3835 3849 10577857
38. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas NCI Sponsored International Working Group. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, et al. J Clin Oncol 1999 17 1244 10561185